Literature DB >> 8245536

Intravitreal ganciclovir concentration after intravenous administration in AIDS patients with cytomegalovirus retinitis: implications for therapy.

B D Kuppermann1, J I Quiceno, M Flores-Aguilar, J D Connor, E V Capparelli, C H Sherwood, W R Freeman.   

Abstract

To determine whether therapeutic intravitreal concentrations of ganciclovir are achieved after intravenous administration, vitreous samples were obtained intraoperatively from 23 eyes of 22 AIDS patients with retinal detachments associated with cytomegalovirus (CMV) retinitis. The mean intravitreal ganciclovir concentration of all samples was 0.93 +/- 0.39 microgram/mL (3.6 +/- 1.5 microM). This level is near the published trough serum concentrations obtained with every-12-h intravenous dosing and well below the peak. It is significantly below the concentration of ganciclovir required to achieve 50% of viral plaque formation for many human CMV strains. Only a small decrease in vitreous drug levels was observed as a function of time after last dose. Intravenous administration of ganciclovir results in near-steady-state subtherapeutic intravitreal ganciclovir concentrations for many CMV isolates. This may explain the difficulty of long-term complete suppression of CMV retinitis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8245536     DOI: 10.1093/infdis/168.6.1506

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

Review 1.  New developments in sustained release drug delivery for the treatment of intraocular disease.

Authors:  G Velez; S M Whitcup
Journal:  Br J Ophthalmol       Date:  1999-11       Impact factor: 4.638

2.  Synthesis and Characterization of Ganciclovir Long Chain Lipid Prodrugs.

Authors:  Kishore Cholkar; Hoang M Trinh; Aswani Dutt Vadlapudi; Ashim K Mitra
Journal:  Adv Ophthalmol Vis Syst       Date:  2014-08-27

3.  Cytomegalovirus retinitis and the acquired immunodeficiency syndrome--bench to bedside: LXVII Edward Jackson Memorial Lecture.

Authors:  Douglas A Jabs
Journal:  Am J Ophthalmol       Date:  2010-12-18       Impact factor: 5.258

4.  High dose intravitreal ganciclovir injection provides a prolonged therapeutic intraocular concentration.

Authors:  N Morlet; S Young; D Naidoo; G Graham; M T Coroneo
Journal:  Br J Ophthalmol       Date:  1996-03       Impact factor: 4.638

5.  The role of ganciclovir for the management of cytomegalovirus retinitis in HIV patients: Pharmacological review and update on new developments.

Authors:  A Tseng; M Foisy
Journal:  Can J Infect Dis       Date:  1996-05

6.  Optimal management of cytomegalovirus retinitis in patients with AIDS.

Authors:  Michael W Stewart
Journal:  Clin Ophthalmol       Date:  2010-04-26

7.  Inhibition of choroidal neovascularization in rats by the urokinase-derived peptide A6.

Authors:  Hyoung J Koh; Kenichiro Bessho; Lingyun Cheng; Dirk-Uwe Bartsch; Terence R Jones; Germain Bergeron-Lynn; William R Freeman
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-02       Impact factor: 4.799

8.  Evolution of Intravitreal Therapy for Retinal Diseases-From CMV to CNV: The LXXIV Edward Jackson Memorial Lecture.

Authors:  Daniel F Martin
Journal:  Am J Ophthalmol       Date:  2018-01-12       Impact factor: 5.258

9.  Population differences in ganciclovir clearance as determined by nonlinear mixed-effects modelling.

Authors:  G J Yuen; G L Drusano; C Fletcher; E Capparelli; J D Connor; J P Lalezari; L Drew; S Follansbee; D Busch; M Jacobson
Journal:  Antimicrob Agents Chemother       Date:  1995-10       Impact factor: 5.191

Review 10.  Ganciclovir. An update of its therapeutic use in cytomegalovirus infection.

Authors:  A Markham; D Faulds
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.